Skip to main content
. 2016 Aug 31;6:32374. doi: 10.1038/srep32374

Figure 2. MiR-3713 targets MMP9 to inhibit its protein translation in TCC cells.

Figure 2

(A,B) The levels of miR-3713 (A) by RT-qPCR and MMP9 (B) by Western blot in TCC cell lines RT4 and T24, compared to TCC tissue from patients. (C) T24 cells were transfected with miR-3713 mimics (miR-3713) or null as a control and examined for miR-3713 levels. (D) RT4 cells were transfected with antisense for miR-3713 (as-miR-3713) or null as a control and examined for miR-3713 levels. (E) Prediction of miR-3713-binding sites on MMP9 mRNA by bioinformatics algorithms. (F–G) The intact 3′-UTR of MMP9 mRNA (MMP9 3′-UTR), together with a 3′-UTR with mutant at miR-3713-binding site of MMP9 mRNA (MMP9 3′-UTR mut), was then cloned into luciferase reporter plasmids. Luciferase activity was determined in RT4 cells (F), which were co-transfected with 1 μg as-miR-3713/null plasmids and 1 μg MMP9 3′-UTR or MMP9 3′-UTR mut plasmids, and in T24 cells (G), which were co-transfected with 1 μg miR-3713/null plasmids and 1 μg MMP9 3′-UTR or MMP9 3′-UTR mut plasmids. *p < 0.05. N = 5.